INTRODUCTION
============

Astrocytes are specialized glial cells that are ubiquitously present in all regions of the CNS (central nervous system). Although astrocytes were first identified over 120 years ago and their responses to CNS injury have been recognized for over a century ([@B86]), for much of this time they have been regarded largely as passive cells providing structural support for neuronal networks; and the notions that astrocytes might make important contributions to CNS function, or that dysfunctions of astrocytes might contribute to CNS pathological remodelling and disease, were generally not considered. In spite of this long 'passive' history, ideas about astrocytes are now changing radically. A steadily growing body of data has over the last 25 years established a variety of essential functions for astrocytes in the healthy nervous system and in the response to injury and disease. Moreover, mechanisms are being elucidated through which the loss or gain of astrocyte functions can contribute to dysfunction or degeneration as well as repair and post-disease remodelling of the CNS. Based on this information, the multiple roles of astroglia, which determine the progression and outcome of neurological diseases, are emerging, and it is becoming clear that astrocytes are involved in various aspects of disease initiation, progression and resolution. Knowledge emerging about many different aspects of neuropathologies clearly indicates that astrocytes contribute to many neurological diseases and in some cases, such as Alexander disease, is the direct cause of the neurodegeneration. As the astrocyte contribution to specific clinico-pathological entities is being defined, it is useful to compare the astroglial involvement across a number of diseases. We will here specifically review the role of astrocytes in epilepsy, stroke and neurodegenerative diseases. Alexander disease presents clinically as a classical early childhood leucodystrophy with seizure, myelin loss and neuronal degeneration, but is caused by mutation and accumulation of GFAP (glial fibrillary acidic protein). The fundamental fact that a defect in astrocytes underlies dysfunction and death of neurons and oligodendrocytes is discussed.

ASTROCYTES CONTROL CNS HOMOEOSTASIS
===================================

Astrocytes are the most numerous, morphologically heterogeneous and functionally diverse neuroglial cells. Indeed, even the definition of astrocyte does not really exist, as the 'astroglia' as a cell class covers all non-myelinating macroglial cells in the CNS, which along with classical protoplasmic and fibrous astrocytes includes, for example, such different cellular entities as retinal Muller radial glial cells, tanycytes in hypothalamus, pituicytes in the neuro-hypophysis, and ependymocytes, choroid plexus cells and retinal pigment epithelial cells that line the ventricles or the subretinal space ([@B148]; [@B199]). All these cells have, however, one thing in common: their main function is in providing for CNS homoeostasis and therefore astrocytes can be broadly defined as 'homoeostatic neuroglial cells'.

Astrocytes participate in controlling CNS homoeostasis at many levels. Astroglia is critical for maintaining molecular homoeostasis (astrocytes regulate concentrations of ions, neurotransmitters and neurohormones in the CNS ([@B128]; [@B37]); metabolic homoeostasis (astroglia accumulate energy substrates and supplies neurones with lactate; [@B103]), cellular homoeostasis (astrocytes are directly involved in neurogenesis; [@B4]), morphological homoeostasis (astroglia define neural cell migration during development, control synaptogenesis/synaptic pruning and shape the micro-architecture of grey matter ([@B125]; [@B143]), and organ homoeostasis (astroglia control the formation and maintenance of the blood--brain barrier; [@B1]). Furthermore, astrocytes appear to be critically important for brain chemosensing, being able to detect systemic fluctuations in CO~2~, pH and Na^+^ and initiate behavioural homoeostatic programmes ([@B168]; [@B57]; [@B77]; [@B56]).

Astrocytes also act as integrators in the CNS. In the grey matter, astrocytes create relatively independent neuro-vascular units connected to the capillaries via astroglial perivascular processes. Recent findings show that astrocytes produce and release various molecular mediators, such as prostaglandin E, nitric oxide and arachidonic acid, which can increase or decrease CNS blood vessel diameter and blood flow in a co-ordinated manner ([@B55]; [@B78]). Furthermore, astrocytes appear to be primary mediators of changes in local CNS blood flow in response to changes in neuronal activity ([@B162]; [@B207]; [@B88]). Astrocytes are fundamental for synaptic transmission and synaptic plasticity. Astrocyte processes that envelop or are in close proximity to synapses provide for spatial specificity of synaptic inputs through isolating individual synapses with astroglial 'cradle' and maintain the fluid, ion, pH and transmitter homoeostasis and provide local metabolic support that are critical for synaptic transmission ([@B14]; [@B127]). Astrocytes are endowed with multiple neurotransmitter receptors that allow them to monitor neuronal activity ([@B198]; [@B91], [@B92]) and, moreover, astrocytes secret multiple neurotransmitters and neurohormones (e.g. ATP/purines, glutamate, [d]{.smallcaps}-serine, etc.: [@B63], [@B64]; [@B166]; [@B141]) that can regulate functional activity of many tens of thousands of synapses located within astroglial territorial domain by a paracrine route. As already mentioned above, astrocyte-derived molecules appear to play critical roles in the formation, maintenance and pruning of synapses ([@B34]; [@B181]; [@B8]). In addition, polypeptide cytokines such as tumour necrosis factor-α produced by astrocytes as well as microglia can influence homoeostatic synaptic scaling by inducing the insertion of AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptors at post-synaptic membranes ([@B180]). Astrocytes are also critical for maintaining glutamatergic transmission by recycling glutamate through the glutamate--glutamine shuttle for subsequent reconversion into active transmitter in the synaptic terminal ([@B37]; [@B159]).

GENERAL PATHOPHYSIOLOGY OF ASTROGLIA: NEUROPATHOLOGY AS HOMOEOSTATIC FAILURE
============================================================================

Every disease of the CNS can be regarded as a homoeostatic failure either inherited (loss of homoeostatic function) or acute (trauma or stroke) or chronic (neurodegeneration). The initiation and progression of these diseases are determined by the degree of homoeostatic loss, which can be either general or function-specific. The general failure is characteristic for acute insults (trauma, stroke or toxic attack), which compromise brain homoeostasis on many levels from organ (disruption of blood--brain barrier) to metabolic (shutting down the brain energetics) and molecular (loss of neurotransmitter homoeostasis with subsequent excitotoxicity). The specific homoeostatic failures are operative in many forms of chronic pathology, when for example down-regulation of glutamate transporters induces neuronal death in Wernicke encephalopathy. In many pathologies, the homoeostatic failure progresses and broadens when for example initial disruptions of protein catabolism trigger inflammatory reactions, initiate cytotoxicity and compromise the blood--brain barrier (as happens in various neurodegenerative processes).

The systemic homoeostatic function of astroglia makes these cells the main targets for neuropathology ([@B51]; [@B201]). Astrocytes form the brain defence system by virtue of many homoeostatic molecules expressed in astroglia; using these molecules, astrocytes contain the damage and sustain neuronal survival through maintaining CNS homoeostasis. One of many examples is represented by maintaining brain metabolism following ischaemia/hypoglycaemia, when astrocyte glycogen breaks down to lactate that is transferred to adjacent neural elements where it is used aerobically as fuel ([@B21]; [@B22]; [@B183]). When and if astroglial homoeostatic mechanisms are exhausted the nervous tissue dies.

At the same time all glial homoeostatic mechanisms are endowed with an inherent dichotomy -- being developed as survivalistic and protective they may turn to be deleterious and toxic. In conditions of severe insult astrocytes can assume damaging and toxic proportions ([Figure 1](#F1){ref-type="fig"}). For example aquaporins expressed in astroglia are critical for water movements through brain tissue, but they can also be instrumental in mediating oedema in pathology ([@B213]). Similarly, K^+^ channels responsible for potassium buffering when under pathological stress can add to accumulation of extracellular K^+^ and mediate spreading depression ([@B124]). The connexins, which connect astrocytes into multicellular syncytia can become the passages for death signals underlying the spread of necrosis through ischaemic penumbra ([@B100]), whereas depolarization and Na^+^ accumulation in astroglia triggers reversal of glutamate transporters which increase glutamate excitotoxicity.

![General pathophysiology of astroglia\
The homoeostatic cascades expressed in astrocytes control various aspects of CNS homoeostasis including extracellular ion homoeostasis (K^+^ buffering via K~ir~ channels, Na/K pump and K transporters), regulate movements and distribution of water (via aquaporins and connexins), control extracellular concentration of neurotransmitters (by dedicated transporters) and provide the main reactive oxygen species scavenging system. In pathological conditions, the very same systems may contribute to brain damage. Failure in water transport triggers brain oedema, reversal of neurotransmitter transporters contributes to glutamate excitotoxicity, inadequate K^+^ buffering promotes further overexcitation of neural cells and spreading depression, and connexins become a conduit for death signals.](an004e082f01){#F1}

ASTROCYTE RESPONSES TO INJURY AND DISEASE: REACTIVE ASTROGLIOSIS AND SCAR FORMATION
===================================================================================

Astrocytes respond to all forms of CNS injury and disease through a process known as reactive astrogliosis. Substantial progress has been made recently in determining functions and mechanisms of reactive astrogliosis and in identifying roles of reactive astrocytes in CNS disorders and pathologies ([Figure 2](#F2){ref-type="fig"}). For the sake of clarity, it is useful to begin with a working definition of the terms 'reactive astrogliosis' and 'glial scar formation' ([@B176]; [@B177]). These terms are not synonymous. Contrary to commonly held beliefs, reactive astrogliosis is not a simple all-or-none stereotypic phenomenon. Instead, reactive astrogliosis is a finely gradated continuum of changes that occur in context-dependent manners regulated by specific molecular signalling events. These changes range from reversible alterations in gene expression and cell hypertrophy with preservation of cellular domains and tissue structure, to long lasting scar formation with rearrangement of tissue structure ([@B176]; [@B177]). Based on a large body of observations in experimental animals and human pathological specimens, a definition of reactive astrogliosis has recently been proposed includes several grades of severity of reactive astrogliosis and glial scar formation that may be encountered in experimental and clinical histopathological examinations ([@B176]; [@B177]). Although the increasing severities of reactive astrogliosis transition seamlessly along a continuum, it is convenient for purposes of description and classification to recognize several broad categories.

![Appearance of astrocytes and different types of reactive astrocytes in mouse cerebral cortex\
Images show immunohistochemistry for the intermediate filament protein, GFAP, which visualizes the cell cytoskeleton. (**A**) In healthy cortex, some, but not all astrocytes express detectable levels of GFAP; cell bodies are small and the cytoskeleton is thin and restricted largely to the proximal portions of cell processes. (**B**) In response to the bacterial antigen, lipopolysaccharide (LPS) injected into the lateral cerebral ventricle, cortical astrocytes become moderately reactive, with up-regulation of GFAP expression such that it is now detectable in all astrocytes. In addition, there is substantial hypertrophy of the astrocyte cell bodies as well as hypertrophy of stem processes and associated cytoskeleton. However, there is no astrocyte proliferation and individual cells continue to respect their individual, non-overlapping domains. (**C**) In response to a severe traumatic injury that creates a lesion (L) with tissue necrosis and invasion of inflammatory cells, astrocytes not only become reactive but also proliferate in the immediate vicinity of the lesion and form a scar with a dense scar border (SB) that comprises many newly generated astrocytes that do not exhibit individual domains and instead have many overlapping and intermingling processes. All images are at the same magnification. Scale bar = 20 μm (Photos courtesy of the Sofroniew laboratory).](an004e082f02){#F2}

Mild to moderate reactive astrogliosis consists of changes (up- or down-regulation) in gene expression and hypertrophy of cell body and processes without substantive loss of individual astrocyte domains and little or no astrocyte proliferation; up-regulation of GFAP expression is prominent. This type of response is generally associated with mild non-penetrating and non-contusive trauma, diffuse innate immune activation (viral infections, system bacterial infections) and areas that are some distance to focal CNS lesions. Because there is little or no reorganization of tissue architecture, if the triggering mechanism is able to resolve, then mild or moderate reactive astrogliosis exhibits the potential for resolution in which the astrocytes return to an appearance similar to that in healthy tissue ([@B176]; [@B177]).

Severe diffuse reactive astrogliosis also consists of changes (up- or down-regulation) in gene expression with pronounced up-regulation of GFAP expression and hypertrophy of cell body and processes, but in addition includes astrocyte proliferation and loss of individual astrocyte domains with substantive intermingling and overlapping of neighbouring astrocyte processes. These changes can result in long-lasting reorganization of tissue architecture that can extend diffusely over substantive areas. This type of response is generally found in areas surrounding severe focal lesions, infections or areas responding to chronic neurodegenerative triggers, and because there can be considerable tissue reorganization, the potential for resolution and return to normal structure is reduced ([@B177]).

Severe reactive astrogliosis with compact glial scar formation also includes changes in gene expression, cellular hypertrophy and astrocyte proliferation, with pronounced overlapping of processes to form compact borders around areas of severe tissue damage, necrosis, infection or autoimmune-triggered inflammatory infiltration ([@B24]; [@B48]; [@B43]; [@B73]; [@B202]). These glial scars include other cell types, in particular fibromeningeal and other glial cells ([@B23]; [@B73]; [@B176]; [@B177]), and deposit collagenous extracellular matrix that contains many molecular cues that inhibit axonal and cellular migration ([@B170]). Triggering insults include penetrating trauma, severe contusive trauma, invasive infections or abscess formation, neoplasm, chronic neurodegeneration, or systemically triggered inflammatory challenges. It is noteworthy that the glial scar formation is associated with substantive tissue reorganization and structural changes that are long lasting and persist long after the triggering insult may have resolved.

The functional roles exerted by reactive astrocytes at different points along their continuum of potential responses to different kinds and severities of CNS insults are only beginning to be understood. Although astrogliosis and scar formation have often been viewed as maladaptive and purely detrimental responses, this is not the case. There are now many different kinds of evidence *in vivo* and *in vitro* that reactive astrocytes maintain their homoeostatic mechanisms and can protect CNS cells and tissue in various ways, including by (i) uptake of potentially excitotoxic glutamate ([@B154]; [@B24]; [@B184]); (ii) protection from oxidative stress via glutathione production ([@B30]; [@B167]; [@B184]; [@B197]); (iii) protection via adenosine release that exerts systemic inhibitory and anti-inflammatory action ([@B99]); (iv) protection from NH~4~^+^ toxicity ([@B147]); (v) protection by degradation of Aβ (amyloid β-peptide; [@B89]); (vi) facilitating blood--brain barrier repair ([@B24]); (vii) reducing vasogenic oedema after trauma, stroke or obstructive hydrocephalus ([@B24]; [@B213]); and (viii) stabilizing extracellular fluid and ion balance and reducing seizure threshold ([@B213]). Different types of transgenic models from different laboratories show that either ablation or attenuation of reactive astrogliosis causes increased lesion size, increased neuronal loss, demyelination and exacerbated loss of function after traumatic injury, stroke, autoimmune attack or infection ([@B24]; [@B48]; [@B120]; [@B135]; [@B43]; [@B73]; [@B96]; [@B202]). Together, these findings indicate that reactive astrocytes exert essential neuroprotective functions. In addition, experimental evidence indicates that reactive astrocytes play important roles in regulating CNS inflammation, and that astrocyte scars act as essential functional barriers that restrict the migration of inflammatory cells and infectious agents and limit spread into adjacent healthy tissue ([@B175]; [@B176]; [@B177]).

THE GENETIC ASTROGLIOPATHOLOGY: ALEXANDER DISEASE
=================================================

In considering how astrocyte dysfunction contributes to neurological disease, interpreting most models and natural diseases is complicated since there is presumed to be pre-existing injury to other cell types that then induces the changes in astrocytes. It is worth considering the simpler situation where astrocytes are clearly the primary instigator of disease -- Alexander disease. This rare disorder arises from mutations in the major intermediate filament protein of astrocytes, GFAP ([@B18]). Although GFAP is expressed at lower levels in a number of cell types throughout the body, many lines of evidence point to initial dysfunction of astrocytes as the key initiating event that then leads to a cascade of effects, ultimately affecting every other cell type in the CNS ([@B19]).

Alexander disease is generally classified among the leucodystrophies because the initial descriptions primarily focused on younger onset patients who had dramatic white matter deficits, especially involving the frontal lobes. From its initial description ([@B2]), the disease was associated with distinctive pathology involving accumulations of cytoplasmic protein aggregates within the cell bodies and processes of astrocytes, known as Rosenthal fibres, which contain GFAP and other proteins ([Figure 3](#F3){ref-type="fig"}). The most common classification is based on age of onset (early, juvenile and adult; [@B97]). The younger patients typically have seizures or any of several psychomotor delays as their initial symptoms, with forebrain predominance to their lesions. In contrast, the older patients typically present with gait disturbances, bulbar signs, or autonomic dysfunction, and have a hindbrain predominance of their lesions, sometimes including atrophy of the medulla and cervical spinal cord. All forms are typically progressive, with median survivals reported as 3.6 years for the early onset group and 8 years for the juvenile group (and undefined for adult) ([@B97]). A more recent classification recommends division into just two groups, Types 1 and 2, based on particular clustering of symptoms ([@B146]). In addition, survival may be longer for both groups than previously imagined.

![Immunostaining for GFAP in brain tissue from mouse models of Alexander disease showing abundant Rosenthal fibres in the periventricular region\
GFAP immunohistochemistry in the periventricular white matter of (**A**) wild-type or (**B**, **C**) knock-in point mutants expressing either R76H or R236H mutant forms of GFAP (equivalent to the common R79H and R239H mutations in human GFAP). Abundant Rosenthal fibres with increased immunoreactivity for GFAP are particularly evident in periventricular and white matter astrocytes of adult mice (3 months old). Reproduced with permission from Figures 3(A)--3(C) of [@B61] ©2006 Society for Neuroscience.](an004e082f03){#F3}

As noted above, all forms of Alexander disease are now associated with mutations in GFAP ([@B97]). Most of these mutations are heterozygous single base pair changes within the coding region that predict single amino acid changes in the translated protein. A small number of mutations involve in frame deletions or insertions. All are heterozygous, genetically dominant, with nearly 100% penetrance. A very small number of patients with presumed Alexander disease have no identifiable coding region mutations, but in theory a similar disease could arise from other types of alterations at the GFAP locus such as promoter mutations or gene duplication. Most mutations occur *de novo* (as expected when survival is short), although later onset patients can survive to reproductive age and transmit the mutations to subsequent generations with typical autosomal dominant patterns of inheritance. A recent population-based survey in Japan reported a prevalence of 1 in 2.7 million, but this value may be low because the study excluded severely affected infants who died at very young ages and adult-onset patients are often missed ([@B212]).

How do GFAP mutations cause disease? There are no clear answers to this question yet, partly a reflection of how little we understand the normal functions of GFAP and other intermediate filaments. It is interesting that the known disease-causing mutations (now numbering 71 out of a total 432 amino acid sequence) are sprinkled throughout the rod and tail domains ([@B19]; <http://www.waisman.wisc.edu/alexander/mutations>). The surprising fact is that all of these mutations essentially cause the same disease. Genotype--phenotype correlations are still only speculative, due in large part to the paucity of patients with any particular mutation. While the R239H mutations seem to consistently cause early onset disease, the R416W mutation has been found in all forms of the disease. Several examples exist of the same mutation causing different forms of the disease, even within the same family ([@B182]; [@B117]). It is possible that head domain mutations do occur, but are early lethal and so never reach the stage of diagnosis.

Unlike most of the other intermediate filament diseases, GFAP mutations appear to act in a gain-of-function fashion. In support of this hypothesis is the absence of truncation or null mutations among the human patients ([@B19]), the dissimilarity in phenotype between mouse knockouts of GFAP and the human disease ([@B54]; [@B138]; [@B109]), and the finding that overexpression of wild-type protein alone to sufficient levels is lethal and replicates the key pathological feature of the disease, Rosenthal fibres ([@B116]). Using cell culture models, [@B186] have found that forced overexpression of wild-type and mutant GFAP leads to pleiotropic effects, with activation of JNK (c-Jun N-terminal kinase) and p38 MLK (mixed-lineage kinase) stress pathways and impairment of the proteasome. One or more positive feedback loops then form to further enhance the toxic accumulation of GFAP. Paradoxically, there is also enhancement of autophagy, which occurs by both mTOR (mammalian target of rapamycin)-dependent and -independent mechanisms ([@B187]). Mouse models show evidence of oxidative stress, particularly in white matter ([@B61]), and the cell culture models display increased sensitivity to camptothecin-induced apoptosis and H~2~O~2~-induced cell death ([@B186]; [@B32]).

How GFAP mutations and/or excess activate these stress pathways and impact on the protein degradation machinery of the cell is not clear. Normally GFAP exists in an equilibrium between Triton-X soluble and insoluble pools, with the majority being insoluble. These two pools roughly correspond to the process by which monomers (which are soluble) gradually assemble into higher-ordered structures and finally mature intermediate filaments (which are insoluble). Expression of mutant GFAPs cause a distinct shift in this equilibrium towards the insoluble pool, perhaps reflecting the unknown proportion that accumulates in the Rosenthal fibres themselves ([@B75]). Interestingly, the shift towards insolubility is also displayed by the small stress protein αB-crystallin, which is a normal-binding partner of GFAP and accumulates in the Rosenthal fibres as well ([@B41]; [@B142]). Studies in mouse models have shown that αB-crystallin deficiency increases mortality ([@B62]). Perhaps αB-crystallin is sequestered to the point of deficiency? Hence, one hypothesis is that the Alexander phenotype reflects a combination of both gain of function (GFAP) and loss of function (αB-crystallin). One cannot blame the full Alexander phenotype on αB-crystallin deficiency alone; however, since mouse knockouts of αB-crystallin and humans with a nearly complete deletion at this locus have predominantly skeletal muscle phenotypes, with no evidence yet for neurological consequences ([@B15]; [@B40]).

Are the astrocytes in Alexander disease simply extreme examples of reactive astrocytes? They do share some properties considered fundamental to the gliotic phenotype, such as increased expression of GFAP and the endothelin B receptor ([@B61]). Recent studies point towards impaired expression of the glutamate transporter Glt-1 ([@B62]; [@B193]), perhaps analogous to what occurs in other neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis). However, as (probably) noted above, reactive astrocytes are highly diverse and likely differ considerably depending on the nature of insult, location in the nervous system, and stage of disease ([@B65]). In the case of Alexander disease, the initial insult is mutant GFAP, which may produce toxic forms that are unique to this condition and cause types of astrocyte dysfunction different from those in other types of reactive astrocytes. Interestingly, the Goldman laboratory has identified toxic oligomers in the soluble pool of GFAP that may be responsible for the impairment in proteasome function noted above, and also showed that this effect could be mitigated by co-expression of the small stress protein, αB-crystallin ([@B185]). That αB-crystallin may be a key modifier of astrocyte function, and potential therapeutic target, is also indicated by its ability to rescue mouse models of Alexander disease from an otherwise lethal phenotype induced by GFAP mutations and excess ([@B62]).

Despite the many gaps in our understanding of the mechanisms and impact of astrocyte dysfunction in Alexander disease, several strategies for therapy have been suggested ([@B115]). The most obvious approach is to reduce the expression or accumulation of GFAP, so as to avoid the initial insult that drives the entire process. One drug screen has already been completed using wild-type astrocytes in primary culture ([@B33]), and similar drug screens using astrocytes expressing mutant protein are underway. A second approach is to target downstream effects of GFAP toxicity, such as the proposed change in Glt-1 expression. Ceftriaxone, already in clinical trials for ALS, may be a good candidate for such an approach ([@B155]). Finally, manipulation of stress pathways such as those regulating αB-crystallin may prove effective. New *Drosophila* models of GFAP toxicity in glia have just been developed that will prove especially valuable for dissecting the pathways to dysfunction, and may even be suitable for drug screening ([@B203]).

THE ACUTE ASTROGLIOPATHOLOGY: ISCHAEMIA AND STROKE
==================================================

Stroke remains a major source of death and disability in the United States as a stroke-induced death occurs every 3 min. Over the past couple of decades, dozens of clinical trials tested neuroprotective agents in the treatment of stroke. These efforts largely targeted neuronal-specific cell death ignoring the roles of other cell types such as astrocytes, microglia and the vasculature. The failure of these trials has evoked a keen interest in elucidating the influence of non-neuronal cell types on brain survival and function during stroke. As discussed in detail at the beginning of this paper a large body of literature supports a pivotal influence of astrocytes on multiple processes within the brain, which impact the survival and function of neurons as well as the vasculature. Yet, astrocyte function may be both protective and harmful. Interestingly, the same molecule released by astrocytes may have opposing actions on brain tissue viability depending on their temporal expression following stroke. Determining the critical temporal windows and the molecular mechanisms by which astrocyte function either reduces or enhances injury is important to discern and will be a matter of the discussion to follow.

During the first few hours after the onset of ischaemia, the acute phase of stroke, several astrocyte functions may reduce ischaemic damage including the uptake of glutamate, scavenging of reactive oxygen species and uptake of K^+^ ([@B29]). Yet many of these functions are likely compromised in the inhospitable environment of the ischaemic brain. In the stroke core, where glucose and oxygen supply are greatly reduced, the severe loss of energy substrates can lead to astrocyte membrane depolarization and death. If the membrane potential of astrocytes is compromised too severely, glutamate flux may reverse leading to release of glutamate by astrocytes and neuronal excitotoxicity. Although astrocytes in culture are more tolerant to OGD (oxygen glucose deprivation) compared with neurons, they are particularly susceptible to damage during acidosis and when ion concentrations of Na^+^ and Ca^2+^ are altered to model those found in the stroke core ([@B52], [@B53]; [@B31]). In fact, some studies suggest that astrocytes may be more vulnerable to ischaemia than neurons ([@B50]; [@B101]), although this point is debated ([@B60]). Regardless, when astrocyte death occurs through necrosis, this unstructured loss of intracellular constituents into the extracellular space would be expected to enhance stroke damage by increasing inflammation and oedema.

Given that cell death in the stroke core occurs early and is overwhelming, research has focused on preventing delayed neuronal death in the stroke penumbra and reducing the growth of stroke volume in the hours and days after stroke onset. One clinical trial manipulated astrocyte function as a means to diminish the delayed growth of stroke volume. One of the mechanisms by which astrocytes likely enhance neuronal death following stroke is through the release of S100β ([@B107]), which is toxic to neurons when present at high levels ([@B76]). AA (arundic acid; ONO-2506) was identified through a chemical screen as a compound that could diminish activation of astrocytes and S100β expression. In fact, AA reduced delayed growth of infarct volume and improved functional outcome in rodents ([@B189]). The protective effect of AA was greater if administered 24 h after stroke onset compared with its administration immediately after stroke onset, suggesting that its window of efficacy is very much extended compared with most neuroprotectants. A multiple-centre trial testing the efficacy of AA to reduce stroke-related disability was conducted. However, this trial was terminated early for lack of efficacy. Yet, clinical studies suggest that growth of stroke volume occurs in a subset of patients ([@B178]; [@B11]; [@B9]). As such, this delayed growth of stroke volume may be a worthy target for future work if this subset of patients can be reliably identified and targeted.

In the days and weeks after stroke onset, astrocytes release a number of neuroprotectants including EPO (erythropoietin), VEGF (vascular endothelial growth factor) and glial-derived neurotrophic factor, all of which may either reduce ischaemic neuronal damage or improve functional recovery following stroke ([@B87]; [@B214]; [@B72]; [@B67]; [@B81]; [@B28]). In particular, the neuroprotective properties of EPO have been studied ([@B106]; [@B105]; [@B156]; [@B145]). For example, EPO reduces neuronal death with OGD ([@B156]), glutamate toxicity ([@B118]), and nitric oxide induced death ([@B157]). Conditioned media taken from hypoxic astrocyte cultures is protective to neurons exposed to OGD through the actions of EPO, demonstrating the importance of astrocytes in mediating neuroprotection under these circumstances ([@B28]). Similar to the *in vitro* experiments, protective effects have been described for EPO *in vivo* during stroke ( [@B12]; [@B174]). Clinical trials were performed to establish the safety and efficacy of EPO in stroke treatment. An initial Phase II trial did not identify any safety concerns and suggested efficacy of EPO protection in acute stroke ([@B45]). A subsequent Phase III double-blinded, placebo-controlled trial enrolled 522 patients ([@B46]). Patients were treated with EPO within 6 h of the onset of their symptoms and clinical outcome was evaluated at 30 and 90 days after stroke ([@B46]). Unfortunately, EPO did not improve clinical outcome compared with the placebo. This negative result reminds us that all neuroprotective trials are hampered by the problem of delivery of a compound to a poorly perfused area of brain within a short time-frame after stroke onset. Yet, EPO could still be a potential agent to improve functional outcome after stroke. For example, EPO has multiple restorative functions, including promoting angiogenesis and neurogenesis ([@B169]; [@B26]; [@B173]). To harness the restorative power of EPO in stroke, it is important to examine the mechanisms by which the temporal expression of endogenous EPO may be enhanced in astrocytes following stroke.

The transition from the acute stroke period to the sub-acute/chronic time frame after stroke can dramatically change the functional consequences of astrocyte-released proteins. Both VEGF and MMP-9 (matrix metalloproteinase-9) have dramatically different effects in the acute versus sub-acute time frames following onset of ischaemia. VEGF is expressed in astrocytes, as well as other cell types, during hypoxia and stroke ([@B172]; [@B93]). While VEGF is neuroprotective in culture ([@B83]), administration of VEGF at the onset of stroke increases stroke volume ([@B81]). This pathological effect of VEGF is mediated by the ability of VEGF to enhance blood--brain barrier permeability, which leads to brain oedema. In contrast, when administered 2 days after stroke onset during the sub-acute stroke period, VEGF enhances angiogenesis and recovery from stroke ([@B81]). Thus, the protective or pathological actions of VEGF are determined by its temporal expression. Similarly, MMP-9 has pathological or adaptive functions depending on its temporal expression following stroke ([@B215]). MMPs cleave extracellular matrix proteins, which are important in modulating cellular interactions during tissue remodelling in disease and trauma. It is well described that MMP-9 increases blood--brain barrier permeability and increases ischaemia-induced damage during acute stroke ([@B36]; [@B82]). In contrast, several days after stroke onset MMP-9 serves a neuroprotective role by cleaving and activating VEGF ([@B215]). During this delayed time-frame, MMP is highly expressed on both astrocytes and neurons. In addition, VEGF localizes primarily to astrocytes, suggesting that astrocytes significantly contribute to this protective function of MMP-9. These temporally distinct and divergent actions of VEGF and MMP-9 demonstrate the important concept that astrocyte function may change from a pathological to adaptive depending on the temporal profile of expression following ischemia. As such, future therapeutics targeting these functions will need to carefully consider these critical time windows for intervention.

In the weeks to months following stroke onset, profound synaptic plasticity occurs in the peri-infarct cortex, which influences functional recovery ([@B27]; [@B130]). Astrocytes have prominent roles in modifying synaptic plasticity and formation of new synapses (see above). Emerging evidence suggests that astrocytes release extracellular matrix proteins that encourage neurite outgrowth and plasticity and therefore may be a target for therapeutic intervention. For example, the TSP1/2 (thrombospondins 1 and 2), which are extracellular glycoproteins, are highly induced after stroke on astrocytes ([@B98]). In cultures, the application of TSP1/2 enhances synaptogenesis several fold ([@B34]). Interestingly, in stroke models, synaptic number and axonal sprouting were reduced in transgenic knockout mice lacking TSP1/2 function ([@B98]). Recovery of functional tests was also diminished in these TSP1/2 KO mice. Based on these results, designing treatments that increase TSP1/2 function or astrocyte release of TSP 1/2 may enhance stroke recovery.

Similar to the above discussions, the effect of reactive astrocytosis is also dependent on its time course after acute head trauma. The role of reactive astrocytes has traditionally been viewed as a process leading to glial scar formation, reducing the ability of the brain to form new synaptic connections and axon outgrowth. Yet, work over the last several years has illustrated that reactive astrocytosis contributes to tissue survival in several conditions, which is in part dictated by the time course after injury in which it occurs. One tool for examining reactive astrocytes is by utilizing transgenic mice with loss of GFAP and vimentin ([@B139]). These mice have diminished reactive astrocytosis. Interestingly, the effect of reactive astrocytosis changes temporally after injury. For example, after neurotrauma, GFAP^−/−^:Vimentin^−/−^ mice have increased loss of synapses during the acute phase of the injury, but synaptic number is enhanced in the weeks following acute injury ([@B206]). In stroke, GFAP^−/−^:Vimentin^−/−^ mice have increased stroke volume, suggesting a protective role under these conditions ([@B96]). Similarly, ablation of proliferating reactive astrocytes enhanced spinal cord injury following spinal cord trauma ([@B48]) and traumatic brain injury ([@B120]), while it also enhanced neurite outgrowth ([@B24]).

THE CHRONIC ASTROGLIOPATHOLOGY: EPILEPSY
========================================

Epilepsy or the occurrence of recurrent seizures is a behavioural syndrome, that is, a component of several neurological conditions. Several brain foci associated with seizure generation are populated by increased numbers of astrocytes. Such foci include hippocampal seizure foci in temporal lobe epilepsy, several types of mass lesions in the brain (low-grade astrocytomas, oligodendrogliomas and arteriovenous malformations) and tuberous sclerosis. Gliotic scar formation is a prominent feature of human epilepsy ([@B49]; [@B140]). What is the role of astrocytes in epileptogenesis in these neurological conditions?

Epileptogenesis literally means the beginning of epilepsy or spontaneous recurrent seizures. Do astrocytes play a role in the mechanisms necessary for spontaneous seizures to first appear or do astrocytes play a role in seizure maintenance in the chronic stages of epilepsy? There is some evidence to support a primary role of astrocytes in seizure generation, particularly in animal models. In the EL (epileptic) mouse the hippocampus is important for the generation of behavioural seizures. However, there is no neuronal injury or loss in this model but an increase in expression of astrocytes around the age when seizures appear ([@B42]), and these astrocytes have reduced glutamate transporters, suggesting a primary role for astrocytes, perhaps through defective glutamate clearance at the seizure focus ([@B79]). More direct evidence is found mice in which there is astrocyte-specific inactivation of the Tsc1 gene (Tsc1 cKO mice). In these mice, there is an increase in proliferating GFAP-immunoreactive astrocytes throughout the brain ([@B195]), with the most distinctive histological alterations seen in the hippocampus. What is significant is that these astrocyte-specific cKO mutant mice did not show cortical tubers or defects in neocortical lamination. These mice have electrographically confirmed seizures shortly after astrocyte proliferation has begun ([@B195]). Further, the astrocytes in Tsc1 cKO exhibit decreased expression of the glutamate transporters GLT-1 and GLAST and a functional decrease in glutamate transport current in astrocytes in hippocampal slices and astrocyte cultures ([@B208]). Such changes in glutamate transporters may lead to the extracellular accumulation of glutamate, which could cause hyperexcitability of neurons and seizures. Cultured Tsc1-deficient astrocytes and hippocampal slices from cKO mice also exhibited reduced Kir currents and decreased expression of specific *K*~ir~ channel protein subunits Kir2.1 and Kir6.1. Thus impaired extracellular K^+^ uptake by astrocytes may also contribute to neuronal hyperexcitability and epileptogenesis in this Tsc1 cKO mouse model ([@B80]).

Much of our understanding of the role of glia in human epilepsy is obtained from the study of seizure foci surgically removed for the control of medically intractable seizures ([@B38]). The one limitation in studying human tissue that it is taken from patients is that they have had seizures for a considerable period (6--20 years) prior to surgery. Thus it is more difficult to draw conclusions from this patient group on the role of astrocytes in the early (acute) stages of epileptogenesis.

The seizure focus that has received the most study is the hippocampus from patients with medically intractable temporal lobe epilepsy. The examination of such hippocampi indicates that approximately 40--65% of these hippocampi have hippocampal sclerosis. Eighty percent of these sclerotic patients have an excellent surgical outcome. The sclerotic hippocampi have a very high density of astrocytes and these astrocytes have many distinctive properties compared with astrocytes from non-sclerotic hippocampi. Differences in these astrocytes are seen in their cell membrane properties -- they show increased expression of the glutamate receptors mGluR2/3 (metabotropic glutamate receptor 2/3); mGluR4, mGluR8 and GluR1 receptors that have an elevated ratio of flip-to-flop mRNA splice variants ([@B164], [@B163]). The expression of membrane transporter molecules is also altered. Prominent among these are aquaporin 4 molecules, where their polarity of distribution on the astrocytes is altered with reduced expression on the perivascular end feet and unchanged on the membrane facing the neuropil. The GABA (γ-aminobutyric acid) transporter GAT-3 (GABA transporter 3) expression is increased on protoplasmic astrocytes in regions of relative neuronal sparing such as dentate gyrus and hilus. There is some disagreement in the literature as to whether the glutamate transporters EAAT1 (excitatory amino acid transporter 1) and EAAT2 are also reduced. The membrane Na^+^ channels and α1C subunit of the calcium ion channels are also up-regulated, suggesting that astrocytes in sclerotic hippocampi have a significant change in their membrane current characteristics. The inwardly rectifying potassium ion (K~ir~4.1) channels are also shown to be impaired, significantly impeding removal of K^+^ ions from the extracellular space ([@B13]; [@B74]; [@B160]). Among the astrocyte specific enzymes, glutamine synthetase activity is reduced ([@B47]), impeding glutamate clearance and thus leading to increases in extracellular glutamate levels ([@B44]). There is also a reduced capacity for glutamine synthesis and ammonia detoxification. Levels of other astrocyte specific enzymes such as GDH (glutamate dehydrogenase), aspartate aminotransferase and lactate dehydrogenase ([@B104]) are also altered in astrocytes in sclerotic hippocampi.

Gene expression studies in sclerotic hippocampi have also suggested changes in the expression of several genes associated with astrocytes. Among those up-regulated are those involved with immune and inflammatory functions, including several chemokines and cytokines, class II MHC antigen genes and interleukins and complement factors ([@B7]; [@B95]). Several molecules associated with the astrocyte/microvascular interface are also altered, in particular increases in EPO-r (EPO receptor), the MDR1 (multidrug resistance gene-1) encoded P-glycoprotein ([@B194]), CD44 and plectin 1 ([@B95]), among others ([@B38]).

Associated with the above molecular anatomical changes in astrocytes in sclerotic hippocampi are also changes in their function. Some astrocytes in primary cultures derived from sclerotic hippocampi and *in vitro* hippocampal slices are capable of generating action potential-like responses in response to depolarizing currents ([@B13]; [@B131]). Astrocytes from sclerotic hippocampi respond to glutamate with elevated intracellular Ca^2+^ release and Ca^2+^ oscillations and waves ([@B94]). Additionally, several lines of evidence suggest that the altered properties of sclerotic astrocytes, particularly down-regulation of glutamine synthetase, also alter glutamine--glutamate cycling in hippocampal seizure foci resulting in increased extracellular glutamate levels before and during seizures ([Figure 4](#F4){ref-type="fig"}).

![Expression of glutamine synthetase immunoreactivity in a non-sclerotic and sclerotic hippocampus\
Glutamine synthetase immunoreactivty in the subiculum/CA1 region in a non-sclerotic \[non-MTLE (mesial temporal lobe epilepsy)\] (**A**) and sclerotic (MTLE) (**G**) hippocampus. Neurologically normal autopsy hippocampus shows a pattern of staining exactly similar to (**A**). (**B**, **C**) in higher magnification shows GS immunopositive astrocytes in both the subiculum and CA1 area of a normal or non-sclerotic hippocampus. The sclerotic hippocampus, in which the subiculum does not have neuronal loss shows GS immunoreactive astrocytes (**H**), whereas the neuron-depleted astrocyte-rich CA1 area (**I**) shows depletion of GS in astrocytes. (**A** and **G**) Scale bar = 0.5 mm. (**B, C, H** and **I**) Scale bar = 100 μm. Reprinted from The Lancet, 363, Eid T, Thomas MJ, Spencer DD, Runden-Pran E, Lai JC, Malthankar GV, Kim JH, Danbolt NC, Ottersren OP, de Lanerolle NC, Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy, 28-37, Copyright (2004), with permission from Elsevier.](an004e082f04){#F4}

More recent studies suggest the recognition of two functional classes of astrocytes. One type, sometimes referred to as GluR cells, is weakly positive for GFAP, expresses AMPA-type glutamate receptors and properties akin to NG2 cells. These cells are excitable ([@B131]). A second type of cell, the GluT cell, is more strongly GFAP positive, is more fibrous in appearance and expresses K^+^ channels, but lack glutamate receptors ([@B108]). Cells similar to GluR and GluT cells have been recognized in the human hippocampus, and though both types are found in normal hippocampi, an almost complete loss GluT cells is reported in sclerotic hippocampi ([@B74]). It is most likely that it is these cells that have impaired K~ir~ channels. Further, the GluR cells in sclerotic hippocampus have increased levels of the Flip isoform of GluR1 receptor, suggesting an increased potential for excitability.

What role do astrocytes play in a mature hippocampal seizure focus? As the above review suggests, they may play several roles. (i) Astrocytes may contribute to the high glutamate levels at seizure foci through defective glutamate clearance, and additionally active release of glutamate from GluR (NG2)-like cells due to enhanced intracellular Ca^2+^ release or by astrocyte swelling due to reduced aquaporin 4 transporters on perivascular end feet ([@B38]). These elevated glutamate levels may activate neurons in surrounding or adjacent undamaged regions such as the subiculum to generate seizure activity. (ii) Defective astrocytes may contribute increased extracellular potassium in the seizure focus. Impaired inwardly rectifying K^+^ channels and decreased water flux due to reduced AQP transporters in astrocytic end feet may be contributory factors. (iii) The presence of excitable GluR or NG2-like cells with more glutamate-sensitive GluR1 receptors in the sclerotic seizure focus may directly contribute to an excitable focus. (iv) Astrocytes may also modulate the microvasculature, leading to vascular permeability and promoting entry of substances such as albumin or circulating leucocytes into the brain parenchyma with consequent seizure promoting effects ([@B38]). (v) The release of inflammatory and immune factors by astrocytes may also contribute to the development of the seizure focus in ways that are only just beginning to be understood.

Another interesting aspect of epilepsy is the destruction and loss of astrocytic domain organization ([Figure 5](#F5){ref-type="fig"}). Several groups have shown that in the normal brain cortical and hippocampal astrocytes are organized in non-overlapping spatial domains with limited interdigitation of processes of adjacent cells ([@B25]; [@B134]; [@B63], [@B64]). Through a process termed 'tiling,' astrocytic processes grow within exclusive territories during development when neuronal and vascular territories are also being established. In the rodent brain, one astrocytic domain encompasses ∼100000 synapses, whereas this number rises to 2000000 synapses in the brain of homo sapiens ([@B25]; [@B133]). Each domain represents an area of the neuropil that is under control of a single astrocyte, being also an entity of synaptic modulation that is independent of neural networking. All synapses within one territory will be contacted by processes from only one single astrocyte. Reactive astrocytes in three very different murine models of epilepsy (post-traumatic injury, genetic susceptibility and systemic kainate exposure) all were associated with a 10-15-fold increase in overlap of processes of neighbouring astrocytes ([@B132]). A similar loss of astrocytic domain organization was noted in tissue surgically resected from patients resilient to medical treatment. It is important to note that astroglial domain organization was preserved in APP transgenic mice expressing a mutant variant of human amyloid precursor protein despite a striking up-regulation in GFAP expression. Thus, while the functional consequences of loss of astrocytic territories have not been established, it appears to be specifically linked to epilepsy. It is tempting to speculate that synapses receiving input from more than one astrocyte may not function optimally.

![Organization of reactive astrocytes in a model of post-traumatic epilepsy induced by cortical injection of a ferrous chloride solution\
(**A**) Site of cortical injury 6 months after injury. The centre of the lesion (yellow asterisk) is surrounded by palisading astrocytes and, at a greater distance, by hypertrophic astrocytes. The mouse exhibited daily multiple generalized grand mall seizures. (**B**) Higher power image of a similar lesion displaying palisading and hyperthrophic astrocytes. White, GFAP; red, Map2; blue, Sytox. (**C**, **D**) Neighbouring astrocytes in control, non-EL brain exhibit little overlap of processes (**C**), whereas extensive overlap of processes between two adjacent astrocytes is evident in a mouse with epilepsy (**D**). Neighbouring astrocytes were duolistically labelled with DiL (green) or DiD (ref). Scale bar = 100 μm (**A**), 50 μm and 10 μm (**B**), 10 μm (**C**, **D**). See [@B132] for details.](an004e082f05){#F5}

Are these changes in astrocytes in the hippocampal seizure focus secondary mechanisms in seizure development or are they causative? Comparison of these observations with animal studies discussed above, where astrocytes appear to have a more primary role in epilepsy, show that at least some of the astrocytic changes in the human focus may be causative, in particular impairment of K~ir~ channels and decreased expression of astrocytic glutamate transporters.

THE CHRONIC ASTROGLIOPATHOLOGY: NEURODEGENERATIVE DISEASES
==========================================================

Neurocentric views dominate our current understanding of neurodegeneration, which is generally defined as a process of neuronal death that underlie specific neurological deficits. At the same time it becomes clear that idiosyncratic lesions associated with different forms of neurodegenerative diseases (such as for example senile plaques or Lewy bodies) appear at the late stages of neurodegenerative pathologies and massive neuronal demise signals terminal stages of the disease. Our knowledge about early stages of neurodegenerative processes (when arguably the disease can be either halted or slowed down) is remarkably limited, and yet data accumulate suggesting that neurodegeneration begins from failures in brain homoeostasis and alterations in connectivity of neural networks that signals early cognitive impairments ([@B190]; [@B84]; [@B126]; [@B71]). The many levels of brain homoeostasis (cellular, micro-architectural, vascular, metabolic, neurotransmitter, ion, etc.) are controlled almost solely by neuroglia; and it is neuroglia that mount brain defence. With this in mind the progression of majority (if not all) of CNS disorders are determined by the ability of neuroglia to keep brain homoeostasis in stressed conditions, and the failure of glia to maintain homoeostatic balance signals irreparable damage and ultimate death of the neural tissue ([@B51]). The pathological potential of astroglia in neurodegeneration is explored only superficially and yet (as we shall overview below) they seem to be involved in both early and late stages of many neurodegenerative diseases.

Astroglia in AD (Alzheimer\'s disease)
--------------------------------------

The pathological potential of neuroglia in *dementia praecox* was for the first time recognized by Alois Alzheimer, who found that glia populated senile plaques and closely contacted damaged neurones ([@B5]). Conceptually there are two types of astroglial reactions observed in AD-affected brain tissues ([Figure 6](#F6){ref-type="fig"}). Astroglial hypertrophy associated with increased GFAP and S100β levels, all indicative of generalized astrogliosis, are often observed in the post-mortem human tissues ([@B10]; [@B58]; [@B123]; [@B119]), and similarly astrogliosis is detected in various AD animal models ([@B122]; [@B149]; [@B71]). There is a degree of correlation between severity of astrogliosis and cognitive decline, although reactive astrocytes are not always associated with senile plaques ([@B171]). The levels of GFAP alone cannot be predictable as little difference in GFAP expression was found in brains from non-demented and demented patients ([@B205]). The second reaction of astroglia to AD progression was found recently in an animal model of familial AD, where reaction is manifest in the generalized decrease of morphological presence of astrocytes signalling astroglial atrophy/degeneration. The atrophic changes in astrocytes were detected in several brain regions, including hippocampus, pre-frontal and entorhinal cortex ([@B136]; [@B90]; [@B137]; [@B211]). The astroglial atrophy preceded the appearance of senile plaques and appeared first (as early as 1-month-old animals) in the entorhinal cortex, the region earliest affected by the AD pathology. Atrophic changes in astroglia were also observed in the neocortices from the post-mortem demented human brains ([@B165]).

![Astrocytes in neurodegeneration\
(**A**) Fluorescence micrographs illustrating a normal hippocampal astrocyte labelled with anti-GFAP antibody with elongated and multiple radial processes in an old (18 months) control animal. (**B**) In age-matched 3×TG-AD animals, astrocytes show a morphological atrophy with a significant reduction in cell soma volume and area as well as a reduction in the number and width of processes. (**C**) Confocal image showing hypertrophic astrocytes (green) concentrated around Aβ plaques (red); occasionally some of the astrocytes show intracellular Aβ accumulation (yellow). Scale bar (**A** and **B**): 10 μm; (**C**): 50 μm.](an004e082f06){#F6}

How do these two concomitant processes may affect homoeostatic/neuroprotective abilities of astrocytes? The answer to this question remains virtually unknown; for example several contradictory reports indicate that astrocytes in AD brain can participate in both clearance and degradation of Aβ ([@B59]; [@B129]) as well as in the production of the latter ([@B70]; [@B153]). Astroglial accumulation and degradation of Aβ was shown *in vitro* ([@B209]) and was observed in post-mortem entorhinal preparations ([@B122]). Furthermore, it was found that reactive astrocytes from AD model mice (Tg2576) express the amyloid-degrading enzyme neprilysin ([@B6]). Astroglial accumulation of Aβ, however, was very rarely found in 3×TG-AD mice ([@B149]; [@B136]). At the same time astroglial production of Aβ was also reported: it appeared that, in conditions of chronic stress or amyloid load, reactive astrocytes begin to express γ-secretase (which normally is expressed only in neurons) and thus contribute to Aβ production ([@B66]; [@B70]; [@B153]). The Aβ was additionally found to remodel astroglial metabolism, although the data remain similarly controversial: both increased ([@B3]) and decreased ([@B179]; [@B161]) glucose utilization by Aβ-treated astrocytes were reported. This polymorphism of pathological astroglial phenotypes most likely results from multifaceted glial reaction to AD-like pathology which includes atrophic and astrogliotic changes.

Astrocytes in ALS
-----------------

Clinical symptoms of ALS result from rapid progressive degeneration of motor neurons in the cortex, in the brain stem and in the spinal cord. Neuroglial reactions are prominent in ALS and most interestingly the early changes (observed in the human SOD1^G93A^ transgenic mouse model) are represented by astroglial degeneration and atrophy which preceded both neuronal death and clinical manifestation ([@B151]; [@B152]). Astrocytes selectively expressing hSOD1 demonstrated glutamate excitotoxicity, and inhibition of SOD1 expression selectively in astrocytes retarded the ALS progression in transgenic animals ([@B210]). At the late disease stages, prominent astrogliosis is observed, although atrophic astrocytes still can be visualized ([@B110]; [@B151]).

Astrocytes in Parkinson\'s disease
==================================

The pathological role of astrocytes in Parkinson\'s disease is unknown; the late stages of the disease are characterized by reactive astrogliosis ([@B111]; [@B114]). The density of astrocytes in the substantia nigra, which is primarily affected by PD pathology, is the lowest in the brain ([@B114]). This may explain specific vulnerability of substantia nigra neurons to stress factors; in addition, astroglial cells are known to protect dopaminergic neurones *in vitro* and are instrumental for neuronal utilization of [L]{.smallcaps}-DOPA ([@B112], [@B113]; [@B114]).

Astrocytes in Wernicke encephalopathy
-------------------------------------

Wernicke encephalopathy, most likely caused by thiamine deficiency which triggers thalamo-cortical lesions resulting in ataxia, ophthalmoplegia and mental changes, is an example of specific astrodegeneration. Indeed the leading mechanism for the cause of severe excitotoxicity and neuronal death in Wernicke encephalopathy is the dramatic (up to 70%) decrease in expression of astroglial glutamate transporters EAAT1 and EAAT2 that compromises glutamate uptake. The decrease in EAAT1/EAAT2 was detected in human post-mortem tissues and in the rat thiamine-deficiency model of the disease ([@B68]; [@B69]). The signs of astroglial atrophy observed in Wernicke encephalopathy also include significant decrease in expression of GFAP, of glutamine synthetase and astroglial GAT-3 ([@B68]; [@B69]).

Astrocytes in non-AD dementia
-----------------------------

Astroglial degeneration is also observed in various forms of non-AD neurodegeneration/dementia. Significant astrodegeneration and astroglial apoptosis was observed in early stages of fronto-temporal dementia; the degree of astrodegeneration was reported to correlate with the severity of dementia ([@B20]). In addition to these atrophic changes, profound astrogliosis was detected in post-mortem tissues form patients with fronto-temporal dementia ([@B85]). In thalamic dementia astrogliosis was suggested to lead to neuronal death ([@B144]). HIV-1-associated dementia is also characterized by astrogliosis and astrodegeneration; the degree of astroglial loss was reported to correlate with cognitive deficit ([@B192]; [@B196]).

Astrodegeneration and astrogliosis drive neurodegeneration?
-----------------------------------------------------------

Analysis of the recent literature indicates the existence of multifaceted astroglial reactions in the progression of various neurodegenerative processes. Almost invariably these reactions are represented by astrodegeneration/astroglial atrophy and reactive astrogliosis. Balance between these two processes can determine the progression and outcome of the disease, thus placing astrocytes at the very core of neurodegenerative pathology ([@B149]; [@B71]; [@B200]; [@B150]). Early astrodegeneration, for example, may be responsible for initial cognitive impairments that accompany early stages of neurodegenerative diseases. It is well demonstrated that the earliest morphological symptoms of AD are represented by synaptic loss and the extent of this loss correlates with the degree of dementia ([@B39]; [@B191]; [@B158]; [@B35]). Astroglial atrophy may indeed be the mechanism of early synaptic failure in neurodegeneration: reduced astroglial coverage impacts upon synaptic metabolic support, synaptic maintenance and neurotransmitter homoeostasis and turnover. Furthermore, astroglial degeneration affects brain homoeostasis and favours excitotoxicity. At the more advanced stages of neurodegeneration appearance of specific lesions triggers reactive astrogliosis and microglial activation, which acting in concert mount neuroinflammatory responses that ultimately lead to neuronal death and brain atrophy. Would this hypothesis survive the scrutiny of experimental test? Only specifically designed research can provide an answer.

CONCLUSIONS: POTENTIAL PATHOLOGICAL CONSEQUENCES OF ASTROCYTE LOSS OR GAIN OF FUNCTIONS
=======================================================================================

Based on the many different essential roles played by astrocytes in the healthy CNS, it appears likely that the loss of normal functions or gain of abnormal effects by astrocytes has the potential to lead to neuronal dysfunction or degeneration. In this regard, the potential for genetic polymorphisms in different individuals to influence astrocyte functions and dysfunctions may be of clinical interest. Both experimental and clinical examples now exist of how loss of astrocyte functions can precipitate neuronal dysfunction or degeneration. Transgenic mouse models show that deletion of genes selectively from astrocytes can lead to non-cell-autonomous neuronal dysfunction and degeneration. For example, selective deletion from astrocytes of either the endoribonuclease, Dicer, or of the Wnt-signalling pathway gene, APC (adenomatous poliposis coli), in both cases leads to cell-non-autonomous neuronal degeneration of cerebellar Purkinje neurons and in the case of Dicer, also of cerebellar granule neurons ([@B188]; [@B203]). Similarly, the loss of function associated with astroglial atrophy can assume pathological relevance in synaptic weakening and decreased neuronal support in various forms of neurodegenerative pathology as discussed above. In addition, gain-of-function transgenic models indicate that selective targeting to astrocytes of a mutant form of the SOD (superoxide dismutase) associated with ALS leads to neuronal degeneration ([@B102]; [@B121]; [@B210]). As the first recognized clinical example of an astrocyte genetic disorder, mutations in the astrocyte protein, GFAP, have been identified as the cause of neuronal dysfunctions, including seizures, in the human clinical syndrome known as Alexander disease. The prominent association of reactive astrocytes with essentially all CNS insults has the potential for the functions or dysfunctions of these cells to influence CNS pathologies. Combination of mouse models of transgenic astrocyte manipulations with experimental models of CNS injury or disease show that genetic modulations of reactive astrogliosis and scar formation can markedly alter tissue repair, disease progression and functional outcome, such that ablation of astrocytes and attenuation of certain astrocyte functions exacerbates disease progression and tissue degeneration and worsens functional outcome ([@B24]; [@B48]; [@B120]; [@B43]; [@B73], [@B96]; [@B202]), whereas deletion of certain astrocyte genes appears to improve outcome in some situations ([@B16], [@B17]; [@B135]). It is also important to acknowledge that human astrocytes are large, complex, and likely terminally differentiated cells. Astrocytes in rodent brains are several-fold smaller and maintain the potential for dividing. The much longer lifespan of humans combined with the more complex population of astrocytes, suggest that human astrocytes may participate to an even greater extent to disease progression than observations in rodent models suggest. Collectively, multiple findings point towards an enormous, yet incompletely understood, potential for astrocytes to contribute to, or play primary roles in, disease processes, tissue repair and functional outcome in a wide variety of clinical conditions ([@B177]), including stroke, epilepsy and neurodegenerative diseases.
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